ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Publishing March 25, 4:00 p.m. ET:

Monitoring and Developing a Volunteer Patient Navigation Intervention to Improve Mammography Compliance in a Safety Net Hospital  (JOP: Special Series)
Margulies, et al.
Request this article

Challenges, opportunities and priorities for advancing breast cancer control in Zambia. A Consultative meeting on breast cancer control (JGO: Special Article)
Cabanes, et al.
Request this article

Establishing cohorts to generate the evidence-base to reduce the burden of breast cancer in Sub-Saharan Africa: Results from a feasibility study in Kenya​ (JGO: Original Report​)
Subramanian, et al.
Request this article

Publishing March 22, 4:00 p.m. ET:

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma (JCO: Original Report)
Anas Younes, et al.
Request this article

Multidisciplinary Care in High-Risk Prostate Cancer Is the New Standard of Care (JCO: Editorial)
Rahul Parikh, et al.
Request this article

Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab (JCO: Editorial)
Paul Barr, et al.
Request this article

Publishing March 21, 4:00 p.m. ET:

Comparison of Population-Based Observational Studies With Randomized Trials in Oncology (JCO: Original Report)
Daniel Spratt, et al.
Request this article

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma (JCO: Original Report)
John Leonard, et al.
Request this article

Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer (JCO PO: Original Report)
Caroline Brenner Thomsen, et al.
Request this article

Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome (JCO PO: Original Report)
Sebastian Lundgren, et al.
Request this article

Publishing March 20, 4:00 p.m. ET:

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study (JCO: Rapid Communication)
Andrew Wei, et al.
Request this article

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer (JCO: Rapid Communication)
Alice T. Shaw, et al.
Request this article

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study (JCO: Rapid Communication)
Scott Kopetz, et al.
Request this article

Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy (JCO CCI: Original Report)
Jessica P. Hwang, et al.
Request this article

Publishing March 19, 4:00 p.m. ET:

Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop—Workshop Proceedings (JCO PO: Special Article)
Reena Philip, et al.
Request this article

Publishing March 18, 4:00 p.m. ET:

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines (JCO: ASCO Special Article)
Hans Messersmith, et al.
Request this article

Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance (JCO: Original Report)
Michael Goggins, et al.
Request this article

Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers (JCO PO: Original Report)
Kabir Mody, et al.
Request this article

Publishing March 15, 4:00 p.m. ET:

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study (JCO: Original Report)
Klaus-Peter Dieckmann, et al.
Request this article

Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease (JCO: Editorial)
Sara Hurvitz, et al.
Request this article


Embargo Information

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.